-
Notable Sema4 Holdings Insider Trades $165K In Company Stock
Thursday, November 11, 2021 - 12:52pm | 472Read More...Isaac Ro, Insider at Sema4 Holdings (NASDAQ:SMFR), made a large buy and sell of company shares on November 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Isaac Ro exercised options to purchase 62,500 Sema4 Holdings...
-
Chief Financial Officer Of Sema4 Holdings Trades $305K In Company Stock
Wednesday, November 3, 2021 - 11:35am | 456Read More...Isaac Ro, Chief Financial Officer at Sema4 Holdings (NASDAQ:SMFR), made a large buy and sell of company shares on October 25, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Isaac Ro exercised options to purchase 125,000...
-
Hologic: Meet Goldman Sach's New 'Conviction Buy'
Friday, December 8, 2017 - 12:56pm | 490Read More...Hologic, Inc. (NASDAQ: HOLX) — the manufacturer of diagnostic products, medical imaging systems and surgical products — is being added to Goldman Sachs' conviction list. The list is made up of Goldman's Buy-rated stocks that analysts said have the best alpha-generation...
-
Goldman Bullish On Agilent Technologies, Raises Price Target To $53
Wednesday, September 7, 2016 - 3:20pm | 250Read More...Goldman Sachs remains bullish on Agilent Technologies Inc (NYSE: A) and raised its price target by $3 to $53, saying the company is "best positioned to benefit from both underlying end-market strength and improving internal execution." The brokerage said both the end-market strength...
-
Goldman Keeps Agilent On Conviction Buy List Following Mixed Q3, Light Guidance
Thursday, August 18, 2016 - 9:01am | 365Read More...Agilent Technologies Inc (NYSE: A) reported its FQ3 results, with the revenue in line with the consensus and EPS ahead of expectations. Goldman Sachs’ Isaac Ro maintains a Buy rating on the company, with a price target of $50. Guidance Conservative Agilent Technologies revised its FY16...
-
Goldman Believes Key Update On Exact Sciences Reimbursement 'Appears Imminent'
Tuesday, June 14, 2016 - 5:35pm | 143Read More...Goldman Sachs analyst Isaac Ro issued an after-hours note Tuesday commenting on intra-day price action in EXACT Sciences Corporation (NASDAQ: EXAS). With EXACT shares up more than 30 percent over the session, Ro noted "an updated USPSTF website which could have bearing on future...
-
Goldman Adds Agilent To Conviction List: 'EPS Drivers Are Underappreciated'
Wednesday, May 11, 2016 - 8:48am | 604Read More...Goldman Sachs has added Agilent Technologies Inc (NYSE: A) to its "Conviction List," saying that the company's "EPS drivers are underappreciated." "[W]e think consensus underappreciates the potential for upside in Agilent's top-line and operating margin performance, both of which we think will...
-
Goldman Removes Hologic From Conviction Buy List, Maintains Buy
Friday, April 29, 2016 - 10:10am | 229Read More...Goldman Sachs’ Isaac Ro believes that with the early adoption curve for Hologic, Inc. (NASDAQ: HOLX)'s tomosynthesis product having played out, “the upside case will rest on the balance of the company’s portfolio,” where expectations are still low. Ro maintained a...
-
Goldman Upgrades Agilent Technologies, FEI Company And Myriad Genetics
Tuesday, December 8, 2015 - 11:19am | 736Read More...Shares of Agilent Technologies Inc (NYSE: A), FEI Company (NASDAQ: FEIC) and Myriad Genetics, Inc. (NASDAQ: MYGN) have all lost about 3 percent in the last five trading days. Goldman Sachs’ Isaac Ro upgraded the ratings on all three companies. While Agilent and FEI are poised to benefit from...
-
Goldman Just Downgraded These Three Life Science Stocks
Tuesday, December 8, 2015 - 9:15am | 626Read More...Shares of PerkinElmer, Inc. (NYSE: PKI), Laboratory Corp. of America Holdings (NYSE: LH) and Danaher Corporation (NYSE: DHR) have all gained close to 15 percent year-to-date. Goldman Sachs’ Isaac Ro downgraded the ratings on all the companies. Although the 2016 fundamentals in Tools...
-
Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere
Thursday, March 26, 2015 - 3:33pm | 362Read More...Myriad Genetics, Inc. (NASDAQ: MYGN) will face mounting evidence in the first-quarter earnings season of dwindling market share and increased price competition, an analyst said Monday. Neutral Ratings Goldman Sachs' Isaac Ro downgraded the molecular diagnostic company to Sell from Neutral...
-
Numerous Analysts Bullish On VWR Following Quiet Period Expiration
Tuesday, November 11, 2014 - 11:57am | 155Read More...On Tuesday , the analyst quiet period on shares of VWR Corp (NASDAQ: VWR) expired. Following the expiration, analysts at multiple firms initiated bullish coverage on the company. Goldman Sachs: Buy rating; $31 price target. Isaac Ro outlined three catalysts: Accelerating growth in...
-
UPDATE: Goldman Sachs Upgrades Thermo Fisher Scientific as End Market Dynamics Improve
Thursday, February 20, 2014 - 9:54am | 105Read More...In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Thermo Fisher Scientific (NYSE: TMO) from Neutral to Buy, and raised the price target from $114.00 to $153.00. In the report, Goldman Sachs noted, “We upgrade shares of Thermo Fisher Scientific (TMO) to Buy from...
-
UPDATE: Goldman Sachs Initiates on FEI On Expectations Of Shares To Perform In Line With LST Coverage
Wednesday, November 20, 2013 - 8:50am | 144Read More...In a report published Tuesday, Goldman Sachs analyst Isaac Ro initiated a Neutral rating on FEI Company (NASDAQ: FEIC) and initiated a price target of $87.00. In the report, Goldman Sachs says "We initiate coverage of FEI Company (FEIC) with a Neutral rating and 12- month price target of $87 that...
-
UPDATE: Goldman Sachs Initiates Coverage on Pall Corp, In-Line Performance Expected
Wednesday, November 20, 2013 - 8:03am | 119Read More...In a report published Tuesday, Goldman Sachs analyst Isaac Ro initiated a Neutral rating on Pall Corporation (NYSE: PLL) and initiated a price target of $80.00. In the report, Goldman Sachs says "We initiate coverage of Pall Corp (PLL) with a Neutral rating and a 12- month price target of $80 that...
